what states have banned semaglutide FDA Warns on Certain Forms of Compounded Compounded Semaglutide & Tirzepatide 2025:

The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide

WeightWatchers to Acquire Sequence, a Digital Health Platform for Clinical Weight Management

Researchers have warned that many women taking glucagon-like peptide-1 (GLP-1) receptor agonists may be unaware of the associated risks of unplanned pregnancy, or potential foetal risks linked to the medications

So it can't be said for certain if his idea was right or wrong

Papillary (70%) and follicular (25%) cancers make up 95% of thyroid cancers and medullary make up 4% (2)